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1. Vaccines are given to 
humans; small 
sample size (<100)
2. Given to healthy 
humans (ensure the 
efficacy of the 
vaccine)
3. Analyze side effects 
4. Dosage: (Upper limit 
vs lower limit) 
Phase II
1. Sample size 
increases (100-1000)
2. More representative 
sample group (age, 
gender, underlying 
diseases); not just 
healthy individuals 
3. Monitoring side 
effects based on 
determined dosage 
Phase III
1. Large sample size 
(13, 060 
participants)






Randomized- Participants had an equal probability of being placed into control vs experimental 
group 
Multicenter- Trials took place at multiple centers (Brazil)
Endpoint driven- At the end of the clinical trial, researchers can use the statistics to conclude 
whether the intervention technique was beneficial 
Double blind- Neither the participants nor the experimenter are aware of which group the 
participants fall into (Control group vs. experimental group); minimize bias 
Placebo controlled- One group is given a placebo vs the other receiving treatment
Adverse reaction- Any reactions that have a casual relationship to vaccination 
Sinovac Vaccine 
● Vaccines work by imitating an infection (usually involving inactivated viral 
components); helps acquire immunity; production of T-lymphocytes (destroy 
infected cells and make antibodies) and B-lymphocytes (target pathogens) 
● Sinovac Vaccine
○ Manufactured by Sinovac Life Sciences (Beijing, China) 
○ Inactivated vaccine- genetic material of the pathogen is eliminated by heat, 
radiation, or chemicals; cannot replicate or cause illness 
○ Immune response is not as strong as live attenuated vaccines (virus is 
weakened; can’t cause major illness but can still replicate) 
○ Less long lasting 




- 18 years or older, both genders, 
healthy/underlying diseases
- Health care professionals in 
close contact with COVID-19 
patients
- Pregnant women, those 
breastfeeding, or plans to 
conceive within three months 




- Randomized based 
on age (18-59 years 
and 60 years and 
older)
- Two randomization 
groups
- 11,800 (18-59 
year-old) 
- 1, 260 elderly 
(above 60 
year-old)
Step 2 Continued 
Assignments (cont.)
- Half of the participants in 
each group were given the 
treatment and half were 
given the placebo
- Used a centralized 





- Vaccine and placebo 
(0.5mL doses) were given 
as IM injections (deltoid)  





- Assessment of efficacy based on 
WHO standards (protection level 
above 50%)
- Primary efficacy endpoint- 
incidence of symptomatic cases 
of COVID-19 two weeks after 
second injection (diagnosed 
clinically)
- Primary safety endpoint- any 
adverse reactions one week after 
vaccination in both groups 
Experimentation
- Vaccine includes 3 ug/ 0.5 
mL of the inactivated 
SARS-CoV-2 virus 
- Adjuvant- aluminium 
hydroxide (helps boost the 
immune response) 
- Antigen remains for a 
longer period of time 
- Placebo- aluminum hydroxide 
in 0.5 mL solution
Discussion Questions 
1. As the vaccine supply increases, do you think the people receiving the 
vaccine should be given a choice as to which one they want to receive?
2. What are your thoughts on the smaller sample size of senior citizens (1,260 
participants above 60) compared to the other group (11,800 18-59 year-old). 
Should this Phase III trial have included more senior citizens because they 
are the most vulnerable group?
3. Moderna has started testing their vaccines on babies and young children, 
do you think that they should’ve started with the older children first? Since 
young children typically do not get severely ill. 
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